Tbo-Filgrastim: A Review in Neutropenic Conditions-Reference-Cited by-同舟云学术

Tbo-Filgrastim: A Review in Neutropenic Conditions

Published:2016-03-29 Issue:2 Volume:30 Page:153-160
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Blair Hannah A.,Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-016-0172-7.pdf

Reference29 articles.

1. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw. 2013;11(10):1266–90.

2. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–212.

3. Gascon P. The evolving role of biosimilars in haematology-oncology: a practical perspective. Ther Adv Hematol. 2015;6(6):267–81.

4. Teva. Teva announces FDA grants approval for tbo-filgrastim for the treatment of chemotherapy-induced neutropenia [media release]. http://ir.tevapharm.com . 30 Aug 2012.

5. European Medicines Agency. Tevagrastim solution for injection or infusion: summary of product characteristics. 2014. http://www.ema.europa.eu . Accessed 18 Mar 2016.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on sargramostim for treatment of acute radiation syndrome;Drugs of Today;2018

2. Bone Marrow Toxicity: White Blood Cells;Side Effects of Medical Cancer Therapy;2018

3. Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System;Journal of Managed Care & Specialty Pharmacy;2017-12